drugset / Trial / NCT04659031
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
Timeline
- Start
- 2021-05-25
- Primary completion
- 2025-01-10
- Completion
- 2025-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulviprubart | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | Ulviprubart | Monoclonal antibody | 0.5 mg/kg | — |
| Subject | Ulviprubart | Monoclonal antibody | 2 mg/kg | — |
| Subject | Ulviprubart | Monoclonal antibody | 5 mg/kg | — |